Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
COMBINATION AND MONOTHERAPY WITH ZIDOVUDINE AND ZALCITABINE IN PATIENTS WITH ADVANCED HIV DISEASE
Autore:
FISCHL MA; STANLEY K; COLLIER AC; ARDUINO JM; STEIN DS; FEINBERG JE; ALLAN JD; GOLDSMITH JC; POWDERLY WG; RAINES CP; MAYJO KJ; KERULY JC; CRAVEN D; HIRSHORN L; HIRSCH MS; JAYAWEERA DT; YOUNG SW; PATRONEREESE J; BRETTLER D; SPERBER K; GERITS P; SEREMETIS S; GILL JC; GELB LD; MCGUIRE ML; STIFFLER T; LEDERMAN MM; CAREY JT; WALLACE M; MACARTHUR RD; BERGE P; MILDVAN D; COREY L; COOMBS RW; CUMMINGS DK; SCHOOLEY RT; RAY MG; WAITE V; KURITZKES DR; FUHRER J; TENZLER RJ; DONLON W; VANDERHORST CM; TROIANI L; HORTON J; LANE TW; MURPHY RR; PHAIR JP; KESSLER HA; BENSON CA; ROSENWALD V; YONREN S; VALENTINE F; HASLETT P; MITSUYASU RT; GUERRO M; GOETZ MB; MATHISEN GE; FRAME PT; BRINKDOPKE J; POWELL T; HOELLE M; MERIGAN TC; SHAFER R; CAIN P; FESSELL J; HENRY K; RHAME F; CHRISTENSON J; STRYKE D; ZINGMAN B; KAHL P; SOEIRO R; CHOI YS; REICHMAN RL; REID J; BLAIR DC; STEIGBIGEL RT; HEWITT RG; CAMERON ML; DONNELLY MA; PACKARD MV; BARTLETT JA; FIFE KH; ZWICKL BW; BORUM J; BURACK JH; DYBECK KA; COLEMAN RL; JOHNSON WR; MCKINLEY GF; GRIECO MH; KOLATCH BR; SEPKOWITZ K; PONTICELLO L; GIORDANO MF; MURRAY HW; GOCKE DJ; FASS RJ; PARA MF; STERN JS; DREW LJ; SPECTOR SA; HAVLIR DV; NUFFER KL; RICHMAN DD; CONNOR EM; KLOSER PC; PICARDI JM; VANMATERMINER C; LEEDOM JM; HOLTOM PD; RICHARDSON W; EHMANN WC; ZURLO JJ; KREHER M; EYSTER ME; HYSLOP NE; MUSHATT DM; HOADLEY DJ; ZACHARY JA; SIMON GL; PARENTI DM; LELACHEUR S; SCHUCK S; HO MT; MCMAHON DK; PAZIN GJ; ROSENER R; CHEESEMAN SH; MANGINI LA; SANDS MG; KAZIAL K; JONES G; PETTINELLI CB; LANDRY B; MARTINEZ AI;
Indirizzi:
UNIV MIAMI,SCH MED,DEPT MED,R-60A,POB 016960 MIAMI FL 33101 HARVARD UNIV,SCH PUBL HLTH BOSTON MA 02115 UNIV WASHINGTON,HARBORVIEW MED CTR SEATTLE WA 98104 ALBANY MED COLL ALBANY NY 12208 JOHNS HOPKINS UNIV HOSP BALTIMORE MD 21205 JOHNS HOPKINS UNIV,NIAID,CLIN TRIALS GRP BALTIMORE MD 00000 BETH ISRAEL HOSP BOSTON MA 02215 MASSACHUSETTS GEN HOSP BOSTON MA 02114 MEM HOSP,NEW ENGLAND AREA COMPREHENS HEMOPHILIA CTR WORCESTER MA 00000 CUNY MT SINAI SCH MED NEW YORK NY 10029 MT SINAI HEMOPHILIA CTR NEW YORK NY 00000 GREAT LAKES HEMOPHILIA CTR MILWAUKEE WI 00000 WASHINGTON UNIV ST LOUIS MO 00000 CASE WESTERN RESERVE UNIV CLEVELAND OH 44106 MED COLL OHIO TOLEDO OH 43699 BETH ISRAEL HOSP NEW YORK NY 00000 UNIV WASHINGTON SEATTLE WA 98195 UNIV COLORADO,HLTH SCI CTR DENVER CO 00000 SUNY STONY BROOK STONY BROOK NY 00000 UNIV N CAROLINA CHAPEL HILL NC 00000 CAROLINAS MED CTR CHARLOTTE NC 28203 MOSES CONE MEM HOSP GREENSBORO NC 00000 NORTHWESTERN UNIV CHICAGO IL 60611 RUSH PRESBYTERIAN HOSP CHICAGO IL 00000 NYU,MED CTR NEW YORK NY 00000 UNIV CALIF LOS ANGELES,CTR CARE LOS ANGELES CA 00000 UNIV CALIF LOS ANGELES,HARBOR MED CTR LOS ANGELES CA 90024 SEPULVEDA VET ADM HOSP LOS ANGELES CA 00000 OLIVE VIEW MED CTR LOS ANGELES CA 00000 UNIV CINCINNATI CINCINNATI OH 00000 STANFORD UNIV STANFORD CA 94305 KAISER PERMANENTE MED CTR SAN FRANCISCO CA 00000 ST PAUL RAMSEY MED CTR MINNEAPOLIS MN 00000 UNIV MINNESOTA MINNEAPOLIS MN 55455 RIVERSIDE MED CTR MINNEAPOLIS MN 00000 MONTEFIORE HOSP & MED CTR BRONX NY 00000 ALBERT EINSTEIN COLL MED BRONX NY 10467 BRONX MUNICIPAL HOSP CTR BRONX NY 00000 UNIV ROCHESTER ROCHESTER NY 00000 SUNY SYRACUSE SYRACUSE NY 00000 SUNY BUFFALO BUFFALO NY 00000 DUKE UNIV,MED CTR DURHAM NC 00000 INDIANA UNIV INDIANAPOLIS IN 46204 UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP SAN FRANCISCO CA 00000 COLUMBIA UNIV,ST LUKES ROOSEVELT HOSP CTR NEW YORK NY 00000 CORNELL UNIV,COLL MED NEW YORK NY 00000 UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH NEW BRUNSWICK NJ 00000 OHIO STATE UNIV COLUMBUS OH 43210 UNIV CALIF SAN DIEGO SAN DIEGO CA 92103 UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH NEWARK NJ 07103 UNIV SO CALIF LOS ANGELES CA 00000 PENN STATE UNIV,COLL MED HERSHEY PA 00000 TULANE UNIV,SCH MED NEW ORLEANS LA 70112 LOUISIANA STATE UNIV,MED CTR,SCH MED NEW ORLEANS LA 70112 GEORGE WASHINGTON UNIV WASHINGTON DC 00000 UNIV PITTSBURGH PITTSBURGH PA 00000 UNIV MASSACHUSETTS,MED CTR WORCESTER MA 00000 BAYSTATE MED CTR SPRINGFIELD MA 01107 FRONTIER SCI & TECHNOL RES FDN INC AMHERST NY 00000 NIAID BETHESDA MD 20892
Titolo Testata:
Annals of internal medicine
fascicolo: 1, volume: 122, anno: 1995,
pagine: 24 - 32
SICI:
0003-4819(1995)122:1<24:CAMWZA>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
IMMUNODEFICIENCY-VIRUS-INFECTION; AIDS-RELATED COMPLEX; PLACEBO-CONTROLLED TRIAL; PHASE-I TRIAL; 2',3'-DIDEOXYINOSINE DDI; DOUBLE-BLIND; 2',3'-DIDEOXYCYTIDINE; AZT; DIDEOXYCYTIDINE; EFFICACY;
Keywords:
HIV INFECTIONS; ZIDOVUDINE; ZALCITABINE; DRUG THERAPY, COMBINATION; ANTIGENS, CD4;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
25
Recensione:
Indirizzi per estratti:
Citazione:
M.A. Fischl et al., "COMBINATION AND MONOTHERAPY WITH ZIDOVUDINE AND ZALCITABINE IN PATIENTS WITH ADVANCED HIV DISEASE", Annals of internal medicine, 122(1), 1995, pp. 24-32

Abstract

Objective: To compare the safety and efficacy of continuing zidovudine therapy with that of zalcitabine alone or zalcitabine and zidovudineused together. Design: A randomized, double-blind, controlled trial. Setting: AIDS Clinical Trials units and National Hemophilia Foundationsites. Patients: 1001 patients with symptomatic human immunodeficiency (HIV) disease and 300 or fewer CD4 cells/mm(3) or asymptomatic HIV disease and 200 or fewer CD4 cells/mm(3) who had tolerated zidovudine therapy for 6 months or more. Intervention: Patients were randomly assigned to receive zidovudine, 600 mg/d; zalcitabine, 2.25 mg/d; or zidovudine, 600 mg/d, and zalcitabine, 2.25 mg/d. Measurements: The primaryend point was time to disease progression or death. Results: The median follow-up time was 17.7 months. The estimated 72-month event-free rates were 70%, 67%, and 73%, respectively, for the zidovudine, zalcitabine, and combination groups (P = 0.26). A trend analysis showed significantly lower progression rates for combination therapy compared withzidovudine therapy as the pretreatment CD4 cell count increased (P = 0.027). For patients with 150 or more CD4 cells/ mm(3), those receiving combination therapy were less likely to have disease progression or to die than were those receiving zidovudine (relative risk, 0.51; 95% Cl, 0.28 to 0.93; P = 0.029). We observed no difference between the zalcitabine and zidovudine groups (relative risk, 0.74; Cl, 0.40 to 1.36; P = 0.33). For patients with 50 to 150 CD4 cells/mm(3) or fewer than50 CD4 cells/mm(3), we found no differences among the treatment groups (P = 0.69 and P = 0.57, respectively). Severe toxic effects occurredless frequently among patients with 150 or more CD4 cells/mm(3). Conclusions: We found no overall benefits of zalcitabine used alone or with zidovudine. However, a trend analysis suggested a better outcome forcombination therapy compared with zidovudine as the pretreatment CD4 cell count increased.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/09/20 alle ore 22:04:23